Ikena Oncology, Inc.
IKNA
$1.14
-$0.01-0.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -18.89% | -32.82% | |||
| Gross Profit | 18.89% | 32.82% | |||
| SG&A Expenses | -25.69% | 58.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.13% | 5.00% | |||
| Operating Income | 23.13% | -5.00% | |||
| Income Before Tax | 5.29% | 11.28% | |||
| Income Tax Expenses | -47.17% | 430.00% | |||
| Earnings from Continuing Operations | 5.53% | 10.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.53% | 10.85% | |||
| EBIT | 23.13% | -5.00% | |||
| EBITDA | 23.28% | -5.05% | |||
| EPS Basic | 5.55% | 10.84% | |||
| Normalized Basic EPS | 18.04% | 7.22% | |||
| EPS Diluted | 5.55% | 10.84% | |||
| Normalized Diluted EPS | 18.04% | 7.22% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||